SCHEMBL425224

SCHEMBL425224

[CH2]C1CCN(C(=O)OC(C)(C)C)CC1

nearest known ligand 0.64

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HPGD P15428 1/20 0.58
PTPN2 P17706 1/20 0.57
PTPN1 P18031 1/20 0.57
PTPN6 P29350 1/20 0.57
RECQL P46063 1/20 0.55
EPHX1 P07099 1/20 0.55
GPR119 Q8TDV5 8/20 0.55
USP2 O75604 1/20 0.55
SMN1; SMN2 Q16637 1/20 0.55
ALDH1A1 P00352 2/20 0.51
MAPT P10636 2/20 0.50
NPC1 O15118 1/20 0.50
MAPK1 P28482 1/20 0.50
HTT P42858 1/20 0.50
RAB9A P51151 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
KDM4E B2RXH2 1/20 0.50
THRB P10828 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1516224 0.89 HPGD (0.51) HPGDPTPN2PTPN1PTPN6RECQL
SCHEMBL16460935 0.89 HPGD (0.51) HPGDPTPN2PTPN1PTPN6RECQL
SCHEMBL310117 0.88 GPR119 (0.67) HPGDRECQLEPHX1GPR119USP2
SCHEMBL13274147 0.86 GPR119 (0.65) HPGDRECQLEPHX1GPR119USP2
SCHEMBL31551882 0.85 GPR119 (0.59) HPGDPTPN2PTPN1PTPN6RECQL
SCHEMBL696090 0.84 HPGD (0.62) HPGDPTPN2PTPN1PTPN6RECQL
SCHEMBL21359212 0.83 EPHX1 (0.62) HPGDRECQLEPHX1GPR119USP2
SCHEMBL1965735 0.82 USP2 (0.61) HPGDPTPN2PTPN1PTPN6RECQL
SCHEMBL16897017 0.82 HPGD (0.60) HPGDPTPN2PTPN1PTPN6RECQL
SCHEMBL15644289 0.82 HPGD (0.60) HPGDPTPN2PTPN1PTPN6RECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 263 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230339904-A1 ISOINDOLINONES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS BIOTHERYX, INC. 2023-10-26 US claimed
CN-108640965-B 2-substituted-18 beta-glycyrrhetinic acid derivative and application thereof 沈阳药科大学 2021-11-05 CN claimed
US-20200236935-A1 a-Amino Acrylate microbicide, and preparation method therefor and uses thereof UNIV NANKAI (CN) 2020-07-30 US claimed
CN-111362933-A α -amino acrylic acid microbicide and preparation method and application thereof 南开大学 2020-07-03 CN claimed
EP-3402791-A1 SUBSTITUTED THIOHYDANTOIN DERIVATIVES AS ANDROGEN RECEPTOR ANTAGONISTS Janssen Pharmaceutica, N.V. (BE) 2018-11-21 EP claimed
CN-108264518-A Benzo tricyclic analog derivative, preparation method and purposes 中国科学院上海药物研究所 2018-07-10 CN claimed
US-10000502-B2 Substituted thiohydantoin derivatives as androgen receptor antagonists JANSSEN PHARMACEUTICA NV (BE) 2018-06-19 US claimed
US-20170233401-A1 SUBSTITUTED THIOHYDANTOIN DERIVATIVES AS ANDROGEN RECEPTOR ANTAGONISTS JANSSEN PHARMACEUTICA NV (BE) 2017-08-17 US claimed
WO-2017123542-A1 SUBSTITUTED THIOHYDANTOIN DERIVATIVES AS ANDROGEN RECEPTOR ANTAGONISTS JANSSEN PHARMACEUTICA NV (BE) 2017-07-20 WO claimed
CN-106928247-A Spiral shell oxindole compounds and its purposes as therapeutic agent 泽农医药公司 2017-07-07 CN claimed
US-20030225106-A1 Substituted alkylamine derivatives and methods of use AMGEN INC. 2003-12-04 US claimed
EP-1358184-A1 SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE Amgen Inc. (US) 2003-11-05 EP claimed
US-20030203922-A1 Substituted amine derivatives and methods of use AMGEN INC. 2003-10-30 US claimed
US-20030195230-A1 Substituted amine derivatives and methods of use AMGEN INC. 2003-10-16 US claimed
EP-1196411-B1 BRADYKININ B1 RECEPTOR ANTAGONISTS PHARMACOPEIA INC (US) 2003-09-17 EP claimed
US-20030134836-A1 Substituted arylamine derivatives and methods of use AMGEN INC. 2003-07-17 US claimed
US-20030125339-A1 Substituted alkylamine derivatives and methods of use AMGEN INC. 2003-07-03 US claimed
US-20020147198-A1 Substituted arylamine derivatives and methods of use AMGEN INC. 2002-10-10 US claimed
WO-2002068406-A2 SUBSTITUTED AMINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF ANGIOGENESIS AMGEN INC. (US) 2002-09-06 WO claimed
WO-2002066470-A1 SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE AMGEN INC. (US) 2002-08-29 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230339904-A1 ISOINDOLINONES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS CSNK1A1, CSNK1D, CSNK1G1 HPGD 488/4885PTPN2 2864/4885PTPN1 2032/4885
US-20170233401-A1 SUBSTITUTED THIOHYDANTOIN DERIVATIVES AS ANDROGEN RECEPTOR ANTAGONISTS AR, SHBG, NR5A1 HPGD 362/4885PTPN2 1886/4885PTPN1 1495/4885
US-10000502-B2 Substituted thiohydantoin derivatives as androgen receptor antagonists AR, SHBG, NR5A1 HPGD 362/4885PTPN2 1886/4885PTPN1 1495/4885
US-20030225106-A1 Substituted alkylamine derivatives and methods of use NAT1, PIGO, AADAC HPGD 358/4885PTPN2 3095/4885PTPN1 2756/4885
US-20030125339-A1 Substituted alkylamine derivatives and methods of use AADAC, NAT1, PIGO HPGD 84/4885PTPN2 3141/4885PTPN1 2862/4885
US-20200236935-A1 a-Amino Acrylate microbicide, and preparation method therefor and uses thereof AASDHPPT, ACE, ADA HPGD 2655/4885PTPN2 2039/4885PTPN1 966/4885
US-20030134836-A1 Substituted arylamine derivatives and methods of use NAT1, AADAC, AHR HPGD 116/4885PTPN2 1168/4885PTPN1 1001/4885
US-20030203922-A1 Substituted amine derivatives and methods of use MAOB, HNMT, FLT4 HPGD 99/4885PTPN2 2824/4885PTPN1 2552/4885
US-20020147198-A1 Substituted arylamine derivatives and methods of use NAT1, AADAC, AHR HPGD 116/4885PTPN2 1168/4885PTPN1 1001/4885
US-20030195230-A1 Substituted amine derivatives and methods of use MAOB, HNMT, FLT4 HPGD 99/4885PTPN2 2824/4885PTPN1 2552/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.